STAT

Buried in Trump’s executive order on drug pricing is a windfall clause for pharma

The pharmaceutical industry could see windfall profits from a little-noticed tweak to the insurance market tucked into the Trump administration’s draft executive order on drug prices, experts say.

The short, technical paragraph calls for the Internal Revenue Service to allow patients with high-deductible health plans to receive care for chronic diseases, including drugs, before meeting their deductibles.

This allowance, known as a “safe harbor,” could be welcome news for patients with chronic conditions like diabetes or asthma stuck with skimpy plans. For example, a diabetes patient could fill her prescription for insulin with just

You're reading a preview, sign up to read more.

More from STAT

STAT5 min readPsychology
Opinion: Bots Started Sabotaging My Online Research. I Fought Back
I launched an online study aimed at understanding what influences eating behaviors and eating disorders among individuals who identify as in LGBTQ+. Little did I know I was actually launching…
STAT3 min read
FDA Approves Alnylam’s Givlaari, Second-ever Drug Based On RNAi
The FDA has approved the second-ever drug based on a Nobel prize-winning technique known as RNA interference, Alnylam’s givosiran. 
STAT4 min read
Trump’s Stalling On Flavored Vape Ban Draws Blowback — And Fears Of Lasting Damage To American Health
The Trump administration’s apparent decision to back off a plan to ban flavored e-cigarettes may be politically expedient but could do lasting damage to American health, tobacco control advocates say.